ABCAM PLC SPON ADS EACH REP 1 ORD SHS.

Abcam plc is a leading life sciences company that provides research tools and services to scientists and researchers around the world. The company was founded in 1998 and is headquartered in Cambridge, UK. Abcam's American Depositary Shares (ADSs) are traded on the Nasdaq stock exchange under the ticker ABCM.

One of the key strengths of Abcam is its expertise in antibody development and production. The company offers a range of high-quality antibodies, proteins, and other research tools that are used in a variety of applications, including drug discovery, diagnostics, and basic research. Abcam's products are known for their quality, specificity, and reproducibility, and the company has built a reputation as a trusted supplier in the life sciences industry.

Another area where Abcam excels is in its commitment to innovation. The company invests heavily in research and development to develop new products and improve its existing offerings. Abcam has a team of over 400 scientists and researchers who work to develop new antibodies and other research tools, and the company collaborates with academic institutions and other companies to advance its research efforts.

Abcam also has a strong track record of financial performance. The company has consistently generated strong revenue growth, and has a solid balance sheet with low debt and ample cash reserves. This has allowed Abcam to continue its investment in research and development, as well as strategic partnerships and acquisitions.

In addition to its antibody development and production business, Abcam also offers a range of related services to support the life sciences industry. This includes custom antibody production, protein analysis, and data analytics. Abcam's services help researchers and scientists to accelerate their research and make new discoveries more quickly.

Abcam has a global presence, with offices and distribution centers in over 130 countries around the world. The company's global distribution network allows it to efficiently and effectively deliver its products and services to customers, regardless of their location.

In recent years, Abcam has continued to expand its product offerings and geographic reach through strategic acquisitions and partnerships. The company acquired Calico Biolabs in 2020, which added a range of advanced proteomics technologies to its portfolio. Abcam has also partnered with several leading life sciences companies to develop new research tools and therapies.

Abcam plc is a leading life sciences company that has built a reputation for its expertise in antibody development and production, commitment to innovation, and strong financial performance. With a range of high-quality products and services, a focus on research and development, and a commitment to meeting the evolving needs of the life sciences industry, the company is well-positioned to continue its success in the years to come.